Elliott Moves To Block Pharma Merger

Dec 10 2013 | 2:24pm ET

Elliott Management today made good on its threat to try to sink the merger of two pharmaceutical distributors.

The activist hedge fund warned that it would not tender its shares in Celesio unless its would-be buyer, McKesson, "offers fair compensation to all Celesio shareholders and bondholders." McKesson's US$8.3 billion deal requires the tendering of 75% of Celesio shares; Elliott currently owns 25.16%.

Even after that stake is diluted by bond conversions, Elliott will still hold a 22.7% voting stake, which should be enough to block the deal.

McKesson can back out of a deal to buy a majority stake in Celesio from Franz Haniel & Cie if 75% of shares are not tendered. But Elliott does not seem concerned that the deal will die.

"We believe Celesio has other paths to maximize shareholder and bondholder value," Elliott said, suggesting that the company could be split: "Sell the wholesale business to a strategic bidder and the pharmacy business to a separate buyer."


In Depth

Q&A: Decathlon Capital On Revenue-Based Alternative Lending

Oct 30 2017 | 3:49pm ET

The explosion in private credit activity since the end of the financial crisis is...

Lifestyle

CFA Institute To Add Computer Science To Exam Curriculum

May 24 2017 | 9:25pm ET

Starting in 2019, financial industry executives sitting for the coveted Chartered...

Guest Contributor

Saxby: Not All EBITDA Is Created Equal

Nov 30 2017 | 8:02pm ET

Record levels of dry powder are driving competition among private equity firms to...